• Something wrong with this record ?

The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study

J. Seitz-Holland, M. Seethaler, N. Makris, J. Rushmore, KK. Cho, E. Rizzoni, M. Vangel, OS. Sahin, C. Heller, O. Pasternak, F. Szczepankiewicz, CF. Westin, J. Lošák, L. Ustohal, J. Tomandl, L. Vojtíšek, P. Kudlička, M. Jáni, TW. Woo, T. Kašpárek,...

. 2022 ; 47 (2) : 524-530. [pub] 20210408

Language English Country Great Britain

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22011565

Grant support
P41 EB015902 NIBIB NIH HHS - United States

E-resources Online Full text

NLK Free Medical Journals from 1994 to 1 year ago
PubMed Central from 2010 to 1 year ago
Europe PubMed Central from 2010 to 1 year ago
ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1994-01-01
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago
Psychology Database (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 33833403
DOI 10.1038/s41386-021-00997-5
Knihovny.cz E-resources

Matrix metalloproteinases 9 (MMP9) are enzymes involved in regulating neuroplasticity in the hippocampus. This, combined with evidence for disrupted hippocampal structure and function in schizophrenia, has prompted our current investigation into the relationship between MMP9 and hippocampal volumes in schizophrenia. 34 healthy individuals (mean age = 32.50, male = 21, female = 13) and 30 subjects with schizophrenia (mean age = 33.07, male = 19, female = 11) underwent a blood draw and T1-weighted magnetic resonance imaging. The hippocampus was automatically segmented utilizing FreeSurfer. MMP9 plasma levels were measured with ELISA. ANCOVAs were conducted to compare MMP9 plasma levels (corrected for age and sex) and hippocampal volumes between groups (corrected for age, sex, total intracranial volume). Spearman correlations were utilized to investigate the relationship between symptoms, medication, duration of illness, number of episodes, and MMP9 plasma levels in patients. Last, we explored the correlation between MMP9 levels and hippocampal volumes in patients and healthy individuals separately. Patients displayed higher MMP9 plasma levels than healthy individuals (F(1, 60) = 21.19, p < 0.0001). MMP9 levels correlated with negative symptoms in patients (R = 0.39, p = 0.035), but not with medication, duration of illness, or the number of episodes. Further, patients had smaller left (F(1,59) = 9.12, p = 0.0040) and right (F(1,59) = 6.49, p = 0.013) hippocampal volumes. Finally, left (R = -0.39, p = 0.034) and right (R = -0.37, p = 0.046) hippocampal volumes correlated negatively with MMP9 plasma levels in patients. We observe higher MMP9 plasma levels in SCZ, associated with lower hippocampal volumes, suggesting involvement of MMP9 in the pathology of SCZ. Future studies are needed to investigate how MMP9 influences the pathology of SCZ over the lifespan, whether the observed associations are specific for schizophrenia, and if a therapeutic modulation of MMP9 promotes neuroprotective effects in SCZ.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011565
003      
CZ-PrNML
005      
20250423101528.0
007      
ta
008      
220425s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41386-021-00997-5 $2 doi
035    __
$a (PubMed)33833403
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Seitz-Holland, Johanna $u Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA $1 https://orcid.org/0000000218152681
245    14
$a The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study / $c J. Seitz-Holland, M. Seethaler, N. Makris, J. Rushmore, KK. Cho, E. Rizzoni, M. Vangel, OS. Sahin, C. Heller, O. Pasternak, F. Szczepankiewicz, CF. Westin, J. Lošák, L. Ustohal, J. Tomandl, L. Vojtíšek, P. Kudlička, M. Jáni, TW. Woo, T. Kašpárek, Z. Kikinis, M. Kubicki
520    9_
$a Matrix metalloproteinases 9 (MMP9) are enzymes involved in regulating neuroplasticity in the hippocampus. This, combined with evidence for disrupted hippocampal structure and function in schizophrenia, has prompted our current investigation into the relationship between MMP9 and hippocampal volumes in schizophrenia. 34 healthy individuals (mean age = 32.50, male = 21, female = 13) and 30 subjects with schizophrenia (mean age = 33.07, male = 19, female = 11) underwent a blood draw and T1-weighted magnetic resonance imaging. The hippocampus was automatically segmented utilizing FreeSurfer. MMP9 plasma levels were measured with ELISA. ANCOVAs were conducted to compare MMP9 plasma levels (corrected for age and sex) and hippocampal volumes between groups (corrected for age, sex, total intracranial volume). Spearman correlations were utilized to investigate the relationship between symptoms, medication, duration of illness, number of episodes, and MMP9 plasma levels in patients. Last, we explored the correlation between MMP9 levels and hippocampal volumes in patients and healthy individuals separately. Patients displayed higher MMP9 plasma levels than healthy individuals (F(1, 60) = 21.19, p < 0.0001). MMP9 levels correlated with negative symptoms in patients (R = 0.39, p = 0.035), but not with medication, duration of illness, or the number of episodes. Further, patients had smaller left (F(1,59) = 9.12, p = 0.0040) and right (F(1,59) = 6.49, p = 0.013) hippocampal volumes. Finally, left (R = -0.39, p = 0.034) and right (R = -0.37, p = 0.046) hippocampal volumes correlated negatively with MMP9 plasma levels in patients. We observe higher MMP9 plasma levels in SCZ, associated with lower hippocampal volumes, suggesting involvement of MMP9 in the pathology of SCZ. Future studies are needed to investigate how MMP9 influences the pathology of SCZ over the lifespan, whether the observed associations are specific for schizophrenia, and if a therapeutic modulation of MMP9 promotes neuroprotective effects in SCZ.
650    _2
$a dospělí $7 D000328
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hipokampus $x diagnostické zobrazování $x patologie $7 D006624
650    _2
$a lidé $7 D006801
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    12
$a matrixová metaloproteinasa 9 $x terapeutické užití $7 D020780
650    12
$a schizofrenie $x farmakoterapie $7 D012559
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Seethaler, Magdalena $u Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Makris, Nikos $u Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA $u Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Rushmore, Jarrett $u Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Cho, Kang-Ik K $u Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Rizzoni, Elizabeth $u Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Vangel, Mark $u Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Sahin, Olcay Senay $u Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA $1 https://orcid.org/000000022242976X
700    1_
$a Heller, Carina $u Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Pasternak, Ofer $u Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA $u Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA $1 https://orcid.org/0000000270786446
700    1_
$a Szczepankiewicz, Filip $u Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA $1 https://orcid.org/000000025251587X
700    1_
$a Westin, Carl-Fredrik $u Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Lošák, Jan $u Department of Psychiatry, Faculty of Medicine of the Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Ustohal, Libor $u Department of Psychiatry, Faculty of Medicine of the Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Tomandl, Josef $u Department of Biochemistry, Faculty of Medicine of the Masaryk University, Brno, Czech Republic
700    1_
$a Vojtíšek, Lubomír $u Central European Institute of Technology, Neuroscience Centre, Masaryk University, Brno, Czech Republic $7 xx0331412
700    1_
$a Kudlička, Petr $u Central European Institute of Technology, Neuroscience Centre, Masaryk University, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Jáni, Martin $u Department of Psychiatry, Faculty of Medicine of the Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Woo, T Wilson $u McLean Hospital and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
700    1_
$a Kašpárek, Tomáš $u Department of Psychiatry, Faculty of Medicine of the Masaryk University and University Hospital Brno, Brno, Czech Republic
700    1_
$a Kikinis, Zora $u Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
700    1_
$a Kubicki, Marek $u Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. kubicki@bwh.harvard.edu $u Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. kubicki@bwh.harvard.edu $u Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. kubicki@bwh.harvard.edu $1 https://orcid.org/0000000239898212
773    0_
$w MED00006658 $t Neuropsychopharmacology $x 1740-634X $g Roč. 47, č. 2 (2022), s. 524-530
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33833403 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20250423101528 $b ABA008
999    __
$a ok $b bmc $g 1789265 $s 1162763
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 47 $c 2 $d 524-530 $e 20210408 $i 1740-634X $m Neuropsychopharmacology $n Neuropsychopharmacology $x MED00006658
GRA    __
$a P41 EB015902 $p NIBIB NIH HHS $2 United States
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options